Challenges to the Development of Personalized Medicine
22 Oct 2012
Prof Franҫoise Meunier, EORTC Director General, and Prof Alexander Eggermont, President of the European Academy of Cancer Sciences talk to ecancer.tv about the challenges associated with the development of personalized medicine, including difficulties raising sufficient funds for European cancer trials, the way this can be addressed by collaborations with academia, and the steps that must be taken to overcome the differences in the agendas of academia and industry.
Watch the interview
Related News
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
